[1]石绣江,朱海艳,梁晓萍,等.基于NLR建立列线图模型预测肝硬化门静脉血栓形成风险[J].医学信息,2024,37(18):29-24.[doi:10.3969/j.issn.1006-1959.2024.18.004]
　SHI Xiu-jiang,ZHU Hai-yan,LIANG Xiao-ping,et al.Establishment of Nomograph Model Based on NLR to Predict the Risk of Portal Vein Thrombosis in Liver Cirrhosis[J].Journal of Medical Information,2024,37(18):29-24.[doi:10.3969/j.issn.1006-1959.2024.18.004]
点击复制

基于NLR建立列线图模型预测肝硬化门静脉血栓形成风险()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年18期
页码:
29-24
栏目:
临床信息学
出版日期:
2024-09-15

文章信息/Info

Title:
Establishment of Nomograph Model Based on NLR to Predict the Risk of Portal Vein Thrombosis in Liver Cirrhosis
文章编号:
1006-1959（2024）18-0019-06
作者:
石绣江1; 朱海艳2; 梁晓萍3; 冯 娟1; 范晓棠1
1.新疆医科大学第一附属医院消化病二科，新疆 乌鲁木齐 830054；2.西安宝石花长庆医院消化血液科，陕西 西安 710201；3.新疆军区总医院空勤科，新疆 乌鲁木齐 830099
Author(s):
SHI Xiu-jiang1; ZHU Hai-yan2; LIANG Xiao-ping3; FENG Juan1; FAN Xiao-tang1
1.The Second Department of Gastroenterology,the First Affiliated Hospital,Xinjiang Medical University,Urumqi 830054,Xinjiang,China;2.Department of Digestion/Blood,Gem Flower Xi’an Changqing Staff Hospital,Xi’an 710201,Shaanxi,China;3.Aircrew Department of General Hospital of Xinjiang Military Region,Urumqi 830099,Xinjiang,China
关键词:
肝硬化; 门静脉血栓形成; NLR; 列线图
Keywords:
Liver cirrhosis; Portal vein thrombosis; NLR; Nomograph
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2024.18.004
摘要:
目的 分析肝硬化门静脉血栓（PVT）形成的相关危险因素，构建相关列线图模型预测肝硬化PVT形成的风险。方法 回顾性分析2014年1月-2021年10月在我院住院诊治的1000例肝硬化患者的临床资料，将2020年12月前收治的设定为建模集（n=810），之后收治的设定为验证集（n=190）。在建模集中以是否有门静脉血栓形成分为PVT组（259例）和N-PVT组（551例）；运用多因素Logistic回归分析筛出肝硬化PVT形成的独立危险因素，重点分析中性粒细胞和淋巴细胞比值（NLR）与肝硬化PVT形成的相关性，基于NLR构建用于预测肝硬化PVT形成风险的列线图模型，并对该模型进行内外部验证。结果 建模集中PVT组的脾切除史占比、PLT、MPV、NLR、MLR、PLR、门静脉主干内径以及脾静脉直径均高于N-PVT组（P＜0.05）；两组年龄、性别、Child-Pugh分级、白蛋白及糖尿病病史比较，差异无统计学意义（P＞0.05）。多因素Logistic回归分析显示，脾切除史、NLR、门静脉主干内径以及脾静脉直径为肝硬化患者PVT形成的独立预测因素（P＜0.05），其中NLR每增加1个单位，肝硬化患者PVT形成风险增加0.527倍（OR=1.527，95%CI：1.373~1.698，P=0.000）；以脾切除史、NLR、门静脉主干内径以及脾静脉直径构建预测肝硬化PVT形成的列线图模型；列线图模型校准曲线显示，建模集和验证集肝硬化患者PVT形成的预测值与实际观测值符合度良好（P＞0.05），ROC曲线下面积（AUC）为0.769（95%CI：0.732~0.805），验证集联合预测的AUC为0.789（95%CI：0.712~0.866）。决策曲线分析结果显示，在大多数合理阈值概率范围内，建模集和验证集中脾切除史、NLR、门静脉主干内径以及脾静脉直径4个指标预测肝硬化PVT形成均具有良好的净收益率，并且基于NLR联合其余3项指标预测的总体净收益率高于单一指标。结论 基于NLR构建的列线图模型可用于准确预测肝硬化PVT形成风险。
Abstract:
Objective To analyze the risk factors of portal vein thrombosis (PVT) in liver cirrhosis, and to construct a relevant nomogram model to predict the risk of PVT in liver cirrhosis.Methods The clinical data of 1000 patients with liver cirrhosis who were hospitalized in our hospital from January 2014 to October 2021 were retrospectively analyzed. The patients admitted before December 2020 were set as the modeling set (n=810), and the patients admitted after December 2020 were set as the validation set (n=190). In the modeling set, the patients were divided into PVT group (259 patients) and N-PVT group (551 patients) according to whether there was portal vein thrombosis. Multivariate logistic regression analysis was used to screen out the independent risk factors of PVT formation in liver cirrhosis, focusing on the correlation between neutrophil-to-lymphocyte ratio (NLR) and PVT formation in liver cirrhosis. Based on NLR, a nomogram model was constructed to predict the risk of PVT formation in liver cirrhosis, and the model was verified internally and externally.Results The proportion of splenectomy history, PLT, MPV, NLR, MLR, PLR, portal vein diameter and splenic vein diameter in PVT group were higher than those in N-PVT group (P<0.05). There was no significant difference in age, gender, Child-Pugh classification, albumin and history of diabetes between the two groups (P>0.05). Multivariate Logistic regression analysis showed that splenectomy history, NLR, main portal vein diameter and splenic vein diameter were independent predictors of PVT formation in patients with cirrhosis (P<0.05). For each unit increase in NLR, the risk of PVT formation in patients with cirrhosis increased by 0.527 times (OR=1.527, 95%CI:1.373-1.698, P=0.000). A nomogram model for predicting PVT formation in liver cirrhosis was constructed based on the history of splenectomy, NLR, portal vein diameter and splenic vein diameter. The calibration curve of the nomogram model showed that the predicted values of PVT formation in patients with cirrhosis in the modeling set and the validation set were in good agreement with the actual observed values (P>0.05). The area under the ROC curve (AUC) was 0.769 (95%CI: 0.732-0.805), and the AUC of the combined prediction of the validation set was 0.789 (95%CI: 0.712-0.866). The results of decision curve analysis showed that within most reasonable threshold probability ranges, the four indicators of splenectomy history, NLR, main portal vein diameter and splenic vein diameter in the modeling set and validation set had good net rate of return for predicting PVT formation in cirrhosis, and the overall net rate of return based on NLR combined with the other three indicators was higher than that based on a single indicator.Conclusion The nomogram model based on NLR can be used to accurately predict the risk of PVT in liver cirrhosis.

参考文献/References:

[1]祁兴顺,杨玲.肝硬化门静脉血栓管理专家共识（2020年，上海）[J].临床肝胆病杂志,2020,36(12):2667-2674.[2]Violi F,Corazza GR,Caldwell SH,et al.Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry[J].Intern Emerg Med,2016,11(8):1059-1066. [3]朱海艳,范晓棠.肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J].实用肝脏病杂志,2022,25(6):848-852.[4]李卿,王丽林.低分子肝素钠抗凝在肝硬化合并门静脉血栓中的应用效果[J].中国医药导报,2018,15(4):69-72.[5]Hanafy AS,Abd-Elsalam S,Dawoud MM.Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J].Vascul Pharmacol,2019,113:86-91.[6]Senzolo M,Garcia-Tsao G,García-Pagán JC.Current knowledge and management of portal vein thrombosis in cirrhosis[J].J Hepatol,2021,75(2):442-453.[7]Kockerling D,Nathwani R,Forlano R,et al.Current and future pharmacol ogical therapies for managing cirrhosis and its complications[J].World J Gastroenterol,2019,25(8):888-908.[8]徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].实用肝脏病杂志,2019,22(6):770-786.[9]Kao JT,Yu CJ,Feng CL,et al.IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients:A cross-sectional study[J].J Microbiol Immunol Infect,2017,50(3):286-296.[10]Praktiknjo M,Trebicka J,Carnevale R,et al.Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis[J].Clin Transl Gastroenterol,2020,11(2):e00123.[11]Zhang JZ,Gu J.Research Progress on Inflammasome and Cancer-associated Thrombosis-Review[J].Journal of Experimental Hematology,2016,24(4):1260-1263.[12]Kapoor S,Opneja A,Nayak L.The role of neutrophils in thrombosis[J].Thromb Res,2018,170:87-96.[13]Manfredi AA,Ramirez GA,Rovere-Querini P,et al.The Neutrophil’s Choice: Phagocytose vs Make Neutrophil Extracellular Traps[J].Front Immunol,2018,9:288.[14]Heestermans M,Salloum-Asfar S,Salvatori D,et al.Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice[J].Blood,2016,127(21):2630-2637.[15]张爱边,张岘,刘畅,等.NLR、PLR、MPV和RDW检测在慢性骨髓增殖性肿瘤血栓形成中的临床意义[J].武汉大学学报(医学版),2023,44(10):1224-1228.[16]Sierawska O,Makowska P,Taskin C,et al.Innate Immune System Response to Burn Damage-Focus on Cytokine Alteration[J].Int J Mol Sci,2022,23(2):716.[17]Xing Y,Tian Z,Jiang Y,et al.A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis[J].Ann Med,2022,54(1):302-309.[18]Li MX,Zhang XF,Liu ZW,et al.Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis[J].Hepatobiliary Pancreat Dis Int,2013,12(5):512-519.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Journal of Medical Information,2018,31(18):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Journal of Medical Information,2022,35(18):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Journal of Medical Information,2019,32(18):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(18):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[6]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(18):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[7]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(18):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[8]黄 明.腹腔镜脾切除术对创伤性脾破裂患者门静脉血栓形成及血清YKL-40的影响[J].医学信息,2022,35(12):134.[doi:10.3969/j.issn.1006-1959.2022.12.032]
　HUANG Ming.Effect of Laparoscopic Splenectomy on Portal Vein Thrombosis and Serum YKL-40 in Patients with Traumatic Splenic Rupture[J].Journal of Medical Information,2022,35(18):134.[doi:10.3969/j.issn.1006-1959.2022.12.032]
[9]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Journal of Medical Information,2022,35(18):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[10]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(18):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]

更新日期/Last Update: 1900-01-01